The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer now has built the drug pipeline it needs to grow in the next ... company said earnings would probably drop this year. To win back investor confidence, Chief Executive Officer Bill Anderson ...

If you’re looking for an OTC medication that’ll ease pain and quell inflammation, there are several great options to choose ...

Additionally, the ophthalmology drug Eylea™ saw an 8.6% increase in sales. However, these positive developments were offset by a 23% decline in sales of Xarelto, which is Bayer's blockbuster ...

likely affecting Bayer’s ability to profit off the drug. These structural issues come alongside overwhelming €34.5 billion debt levels, close to the company’s annual sales. The ratings body ...

While company spending at Genentech went down in the first year, it shot right back ... thinning drug Xarelto. Anderson said the drug was once responsible for a significant amount of Bayer's ...

Health-care providers and insurance companies can play a key role in educating, empowering, and supporting women in their ...

Pharma head says Bayer has a solid drug pipeline to grow The company’s debt is about €38 billion after Monsanto deal Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing ...